Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for BAX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -117.00M
March 31, 2026 -133.00M
December 31, 2025 -198.00M
September 30, 2025 -111.00M
June 30, 2025 -115.00M
March 31, 2025 3.265B
December 31, 2024 -205.00M
September 30, 2024 -164.00M
June 30, 2024 -91.00M
March 31, 2024 -166.00M
December 31, 2023 -230.00M
September 30, 2023 3.786B
June 30, 2023 -173.00M
March 31, 2023 -170.00M
December 31, 2022 -256.00M
September 30, 2022 -184.00M
June 30, 2022 -187.00M
March 31, 2022 -304.00M
December 31, 2021 -10.27B
September 30, 2021 -207.00M
June 30, 2021 -188.00M
March 31, 2021 -538.00M
December 31, 2020 -264.00M
September 30, 2020 -157.00M
June 30, 2020 -154.00M
Date Value
March 31, 2020 -604.00M
December 31, 2019 -421.00M
September 30, 2019 -231.00M
June 30, 2019 -147.00M
March 31, 2019 -301.00M
December 31, 2018 -216.00M
September 30, 2018 -161.00M
June 30, 2018 -165.00M
March 31, 2018 -374.00M
December 31, 2017 -222.00M
September 30, 2017 -775.00M
June 30, 2017 -196.00M
March 31, 2017 -117.00M
December 31, 2016 -179.00M
September 30, 2016 -166.00M
June 30, 2016 -169.00M
March 31, 2016 -201.00M
December 31, 2015 -232.00M
September 30, 2015 -215.00M
June 30, 2015 -590.00M
March 31, 2015 -770.00M
December 31, 2014 3.00M
September 30, 2014 -619.00M
June 30, 2014 -542.00M
March 31, 2014 -384.00M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Becton, Dickinson & Co. -228.00M
DexCom, Inc. 329.80M
Boston Scientific Corp. -1.956B
West Pharmaceutical Services, Inc. -43.20M
Abbott Laboratories -673.00M